Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical...

Full description

Bibliographic Details
Main Authors: Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Alessandro Fiorentini, Attilio Olivieri, Massimo Offidani
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cells
Subjects:
multiple myeloma
autologous stem cell transplantation
induction
consolidation
maintenance
Online Access:https://www.mdpi.com/2073-4409/11/4/606

Internet

https://www.mdpi.com/2073-4409/11/4/606

Similar Items